JO3006B1 - املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك - Google Patents

املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك

Info

Publication number
JO3006B1
JO3006B1 JOP/2006/0300A JOP20060300A JO3006B1 JO 3006 B1 JO3006 B1 JO 3006B1 JO P20060300 A JOP20060300 A JO P20060300A JO 3006 B1 JO3006 B1 JO 3006B1
Authority
JO
Jordan
Prior art keywords
phenoxy
thio
lysine salts
acetic acid
acid derivatives
Prior art date
Application number
JOP/2006/0300A
Other languages
English (en)
Inventor
F Abdel-Magid Ahmed
Roessler Armin
Mehrman Steven
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3006B1 publication Critical patent/JO3006B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings

Abstract

يتعلق الاختراع الحالي باملاح ليسين مبتكرة وتركيبات صيدلانية تحتويها واستعمالها في معالجة خلل وحالات يتوسطها بي بي ايه ار دلتا.كما يتعلق الاختراع الحالي بعملية مبتكرة لتحضير أملاح الليسين المذكورة.
JOP/2006/0300A 2005-09-14 2006-09-07 املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك JO3006B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71713705P 2005-09-14 2005-09-14

Publications (1)

Publication Number Publication Date
JO3006B1 true JO3006B1 (ar) 2016-09-05

Family

ID=37865545

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2006/0300A JO3006B1 (ar) 2005-09-14 2006-09-07 املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك

Country Status (24)

Country Link
US (2) US7709682B2 (ar)
EP (1) EP1937065B1 (ar)
JP (1) JP5467770B2 (ar)
KR (5) KR20180079468A (ar)
CN (1) CN101304656B (ar)
AR (1) AR058044A1 (ar)
AU (1) AU2006291006B2 (ar)
BR (1) BRPI0615835B8 (ar)
CA (1) CA2622722C (ar)
DK (1) DK1937065T3 (ar)
ES (1) ES2535427T3 (ar)
GT (1) GT200600420A (ar)
HK (1) HK1122699A1 (ar)
HN (1) HN2006032171A (ar)
HU (1) HUE025185T2 (ar)
JO (1) JO3006B1 (ar)
NZ (1) NZ566504A (ar)
PE (1) PE20070434A1 (ar)
PL (1) PL1937065T3 (ar)
PT (1) PT1937065E (ar)
SI (1) SI1937065T1 (ar)
TW (1) TWI414510B (ar)
UY (1) UY29791A1 (ar)
WO (1) WO2007033231A2 (ar)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1670744T1 (sl) 2003-09-19 2010-11-30 Janssen Pharmaceutica Nv fenoksialkil tio fenoksiocetne kisline in analogi
US7301050B2 (en) * 2003-09-19 2007-11-27 Janssen Pharmaceutical N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
UY30288A1 (es) * 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス，インコーポレイティド 小型高密度ｌｄｌ粒子を減少させる方法
US20160016982A1 (en) * 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2011014766A2 (en) 2009-07-31 2011-02-03 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
SI2531200T1 (sl) * 2010-02-06 2017-12-29 Grunenthal Gmbh Kristalizacijski postopek in biološka raspoložljivost
BR112013004882A2 (pt) 2010-08-31 2016-05-03 Snu R&Db Foundation utilização de reprogramação fetal de agonista ppar delta
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
US20160279085A1 (en) * 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
WO2015077154A1 (en) 2013-11-20 2015-05-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
US9486428B2 (en) 2014-03-20 2016-11-08 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
PT3129018T (pt) * 2014-04-11 2020-01-15 Cymabay Therapeutics Inc Tratamento de nafld e nash
SG11201610243YA (en) 2014-06-26 2017-01-27 Cymabay Therapeutics Inc Treatment of severe hypertriglyceridemia
RU2018144286A (ru) * 2016-05-16 2020-06-17 ГБ001, Инк Кристалл производного хинолина
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US20190076500A1 (en) 2017-09-13 2019-03-14 Novartis Ag Combinations comprising fxr agonists
WO2019067373A1 (en) 2017-09-26 2019-04-04 Cymabay Therapeutics, Inc. TREATMENT OF CHOLESTATIC PRURIT
BR112021009038A2 (pt) 2018-11-16 2021-08-10 Cymabay Therapeutics, Inc. tratamento combinado de nafld e nash
WO2020102351A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
US20230008367A1 (en) 2019-09-26 2023-01-12 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2021097027A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of alcoholic liver disease
US20210145775A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of intestinal barrier dysfunction and associated diseases
WO2021098885A1 (zh) * 2019-11-21 2021-05-27 杭州百诚医药科技股份有限公司 α-氟代查耳酮类衍生物及其应用
KR20230107700A (ko) 2021-02-01 2023-07-17 사이머베이 쎄라퓨틱스, 인코퍼레이티드 셀라델파르에 의한 담관병증의 치료
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460689C3 (de) 1974-12-20 1980-06-26 Klinge Pharma Gmbh & Co, 8000 Muenchen 13-disubstituierte Propanol-(2)-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US4125732A (en) 1977-05-06 1978-11-14 American Cyanamid Company 2-Aryloxy-2-(phenoxyalkoxy)phenyl acetic acid and esters
DE3026924A1 (de) 1980-07-16 1982-02-18 Klinge Pharma GmbH & Co, 8000 München 1,3-diphenoxypropan-2-ol-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3028776A1 (de) 1980-07-29 1982-02-25 Klinge Pharma GmbH & Co, 8000 München Neue 1,3-diphenoxypropan-2-on-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3169761D1 (en) 1981-01-09 1985-05-09 Fisons Plc Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them
JPS58177934A (ja) 1982-04-13 1983-10-18 Takeda Chem Ind Ltd ベンゾキノン誘導体
ATE22072T1 (de) 1982-09-30 1986-09-15 Merck Frosst Canada Inc Leukotrienantagonisten, deren herstellung und diese enthaltende zusammensetzungen.
US4820867A (en) * 1983-04-21 1989-04-11 Merck Frosst Canada, Inc. Phenoxypropoxy halophenylacetic acids as leukotriene antagonists
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
JPS61268651A (ja) 1985-05-23 1986-11-28 Takeda Chem Ind Ltd フエニル酢酸誘導体およびその製造法
EP0204349A3 (de) 1985-06-01 1990-01-03 Dr. Karl Thomae GmbH Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH0714910B2 (ja) * 1988-12-13 1995-02-22 塩野義製薬株式会社 安定な結晶性の塩およびそれを含有するトロンボキサン受容体拮抗剤
US5487008A (en) 1990-04-20 1996-01-23 The Regents Of The University Of Michigan Method and system for detecting the misfire of a reciprocating internal combustion engine in frequency domain
CA2092152A1 (en) * 1992-03-23 1993-09-24 Azuma Igarashi Phenoxyacetic acid compounds and medical preparations containing them
US5726165A (en) 1994-07-29 1998-03-10 Smithkline Beecham P.L.C. Derivatives of 4-(2-aminoethyl)phenoxymethyl-phosphonic and -phosphinic acid and pharmaceutical and veterinary uses therefor
WO1997027847A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method of treating diabetes and related disease states
ES2202582T3 (es) 1996-02-02 2004-04-01 MERCK & CO., INC. Agentes antidiabeticos.
JP3268242B2 (ja) 1996-11-14 2002-03-25 三共株式会社 縮合複素環化合物を含有する医薬
ATE421336T1 (de) 1997-07-24 2009-02-15 Astellas Pharma Inc Medizinische zusammensetzungen mit cholesterin erniedrigender wirkung
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
CZ20033309A3 (cs) 2001-06-07 2004-05-12 Eliálillyáandácompany Modulátory receptorů aktivovaných peroxizomálními proliferátory }PPARB
RU2004105956A (ru) 2001-07-30 2005-03-27 Ново Нордиск А/С (DK) Новые производные винилкарбоновых кислот и их применение в качестве антидиабетических средств и т.п.
EP1424330B1 (en) 2001-08-10 2011-09-28 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-responsive receptor delta
ATE434616T1 (de) 2001-10-12 2009-07-15 Nippon Chemiphar Co Aktivator des peroxisomproliferator-aktivierten rezeptors delta
ITRM20020014A1 (it) 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
US7319104B2 (en) 2002-03-01 2008-01-15 Smithkline Beecham Corporation hPPARs activators
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
GB0214149D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
BR0314335A (pt) * 2002-09-05 2005-07-26 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade
AU2003273783C1 (en) * 2002-10-28 2010-08-12 Vtv Therapeutics Llc Novel compounds and their use as PPAR-modulators
MXPA05004405A (es) * 2002-10-28 2005-07-05 Novo Nordisk As Compuestos novedosos utiles en el tratamiento de enfermedades mediadas por ppar.
BRPI0407487A (pt) 2003-02-14 2006-02-14 Biogen Idec Inc cassete e um vetor de expressão para a expressão transitória ou estável de moléculas exógenas
JP2007502815A (ja) 2003-08-20 2007-02-15 イーライ リリー アンド カンパニー Ｐｐａｒ調節因子
US7301050B2 (en) 2003-09-19 2007-11-27 Janssen Pharmaceutical N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
SI1670744T1 (sl) 2003-09-19 2010-11-30 Janssen Pharmaceutica Nv fenoksialkil tio fenoksiocetne kisline in analogi
EA009804B1 (ru) 2003-10-31 2008-04-28 Янссен Фармацевтика Н.В. Производные феноксиуксусных кислот, применимые в качестве двойных агонистов активируемого пероксисомным пролифератором рецептора (ppar)
JP2007533754A (ja) 2004-04-21 2007-11-22 シェーリング　コーポレイション ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ−［１，５−ｃ］−ピリミジンアデノシンＡ２ａレセプターアンタゴニスト
KR100843028B1 (ko) 2004-07-01 2008-07-01 에프. 호프만-라 로슈 아게 아세틸렌기를 포함하는 페닐 유도체
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
MY145712A (en) 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
GB0618963D0 (en) 2006-09-26 2006-11-08 Ucl Business Plc Formulations and composites with reactive fillers

Also Published As

Publication number Publication date
KR20130100800A (ko) 2013-09-11
KR20150013952A (ko) 2015-02-05
EP1937065A4 (en) 2010-07-21
BRPI0615835B8 (pt) 2021-05-25
BRPI0615835B1 (pt) 2020-04-22
AR058044A1 (es) 2008-01-23
BRPI0615835A2 (pt) 2011-05-31
CA2622722C (en) 2016-04-19
TWI414510B (zh) 2013-11-11
PE20070434A1 (es) 2007-05-14
KR20160079129A (ko) 2016-07-05
AU2006291006A1 (en) 2007-03-22
GT200600420A (es) 2007-05-08
HUE025185T2 (en) 2016-02-29
JP2009514797A (ja) 2009-04-09
SI1937065T1 (sl) 2015-05-29
NZ566504A (en) 2010-11-26
HK1122699A1 (en) 2009-05-29
US20070060649A1 (en) 2007-03-15
US7709682B2 (en) 2010-05-04
EP1937065B1 (en) 2015-01-28
WO2007033231A2 (en) 2007-03-22
ES2535427T3 (es) 2015-05-11
US20110105616A1 (en) 2011-05-05
EP1937065A2 (en) 2008-07-02
HN2006032171A (es) 2011-03-15
JP5467770B2 (ja) 2014-04-09
AU2006291006B2 (en) 2012-09-13
WO2007033231A3 (en) 2007-10-11
TW200804256A (en) 2008-01-16
CA2622722A1 (en) 2007-03-22
KR20180079468A (ko) 2018-07-10
KR20080046695A (ko) 2008-05-27
PT1937065E (pt) 2015-03-04
DK1937065T3 (en) 2015-02-09
UY29791A1 (es) 2006-12-29
US8669288B2 (en) 2014-03-11
CN101304656B (zh) 2013-03-13
CN101304656A (zh) 2008-11-12
PL1937065T3 (pl) 2015-07-31

Similar Documents

Publication Publication Date Title
JO3006B1 (ar) املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
BRPI0409109A (pt) novos compostos
CY1112853T1 (el) Ενδιαμεση ενωση 4-(ακετυλαμινο)-3-[(4-χλωροφαινυλ)θειο]-2-μεθυλ-1η-ινδολη-1-οξικο οξυ αιθυλεστερα
NO20016001D0 (no) Substituert fenylpropansyrederivater som agonister for human peroksisom proliferantaktivert reseptor (PPAR)<alfa>
WO2005018529A3 (en) Phenoxiacetic acid derivatives
MX2011009244A (es) Derivado de piridina.
WO2005115383A3 (en) Substituted triazoles as modulators of ppar and methods of their preparation
TNSN05206A1 (en) 3-methyl-2-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis
MX2009012371A (es) Metabolitos de derivados de (tio)-carbamoil-ciclohexano.
MX2012007030A (es) Derivados de acido carboxilico de pirrolidina o tiazolidina, composicion farmaceutica y metodos para su uso en el tratamiento de transtornos metabolicos, como agonistas del receptor 43 acoplado por proteina-g (gpr43).
TW200700069A (en) Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
ATE539750T1 (de) Trans-4-ä2-ä4-(2,3-dichlorophenyl)-piperazin-1- ylü-ethylü-n,n-dimethylcarbamoyl-cyclohexylamin zur behandlung von schizophrenie
PH12014500997B1 (en) 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
MX2008010884A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1.
NO20051011L (no) Kirale oksazol-arylpropionsyrederivater og anvendelse derav som PPAR agonister
WO2007025897A3 (en) Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
UA89067C2 (ru) Производные гидантоина, полезные как ингибиторы металлопротеиназ
UA99109C2 (ru) Производные пиперидин- или пиперазинзамещенной тетрагидронафталин-1-карбоновой кислоты, ингибирующие mtp
WO2006020916A3 (en) Modulators of ppar and methods of their preparation
EA200600878A1 (ru) Производные феноксиуксусных кислот, применимые в качестве двойных агонистов активируемого пероксисомным пролифератором рецептора ( ppar )
UA102397C2 (ru) Производные индола как активаторы nurr-1 и их применение для лечения болезни паркинсона
MX2022015524A (es) Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas.
ATE432262T1 (de) Pyrazolphenylderivate als ppar-aktivatoren
ATE475642T1 (de) Phenoxyessigsäurederivate als ppar-agonisten